Arete Wealth Advisors LLC Reduces Position in Astera Labs, Inc. $ALAB

Arete Wealth Advisors LLC reduced its position in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 11.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,050 shares of the company’s stock after selling 900 shares during the period. Arete Wealth Advisors LLC’s holdings in Astera Labs were worth $421,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Astera Labs by 0.9% in the first quarter. Vanguard Group Inc. now owns 9,297,476 shares of the company’s stock valued at $554,780,000 after buying an additional 85,846 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Astera Labs by 114.2% in the 1st quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company’s stock valued at $501,289,000 after acquiring an additional 4,478,741 shares during the last quarter. Atreides Management LP raised its position in shares of Astera Labs by 153.3% during the 1st quarter. Atreides Management LP now owns 4,652,264 shares of the company’s stock worth $277,601,000 after acquiring an additional 2,815,614 shares in the last quarter. Fred Alger Management LLC raised its position in shares of Astera Labs by 13.0% during the 1st quarter. Fred Alger Management LLC now owns 1,560,033 shares of the company’s stock worth $93,087,000 after acquiring an additional 179,638 shares in the last quarter. Finally, Altimeter Capital Management LP lifted its stake in Astera Labs by 68.0% during the first quarter. Altimeter Capital Management LP now owns 981,697 shares of the company’s stock worth $58,578,000 after purchasing an additional 397,267 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Astera Labs Price Performance

Shares of NASDAQ:ALAB opened at $230.37 on Thursday. The stock has a market cap of $38.29 billion, a P/E ratio of 411.38, a P/E/G ratio of 5.44 and a beta of 1.48. The firm has a fifty day moving average price of $149.50 and a 200 day moving average price of $101.61. Astera Labs, Inc. has a 1-year low of $38.14 and a 1-year high of $230.88.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The company had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. During the same period in the previous year, the business posted $0.13 earnings per share. Astera Labs’s quarterly revenue was up 149.5% on a year-over-year basis. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Sell-side analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on ALAB shares. Morgan Stanley increased their price target on shares of Astera Labs from $155.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, August 29th. Wall Street Zen raised shares of Astera Labs from a “hold” rating to a “buy” rating in a research report on Saturday, August 16th. Susquehanna lifted their price target on shares of Astera Labs from $80.00 to $125.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Stifel Nicolaus set a $145.00 price target on shares of Astera Labs and gave the company a “buy” rating in a research report on Monday, August 4th. Finally, Needham & Company LLC raised their price objective on Astera Labs from $100.00 to $170.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $142.00.

Insider Buying and Selling

In other Astera Labs news, CFO Michael Truett Tate sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $171.38, for a total transaction of $17,138,000.00. Following the completion of the sale, the chief financial officer directly owned 518,996 shares of the company’s stock, valued at $88,945,534.48. This represents a 16.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Sanjay Gajendra sold 280,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $170.02, for a total value of $47,605,600.00. Following the sale, the chief operating officer directly owned 5,525,545 shares of the company’s stock, valued at $939,453,160.90. The trade was a 4.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,832,489 shares of company stock worth $264,172,396. Insiders own 12.50% of the company’s stock.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.